P Fishman

Summary

Affiliation: Tel Aviv University
Country: Israel

Publications

  1. ncbi request reprint Targeting the A3 adenosine receptor for cancer therapy: inhibition of prostate carcinoma cell growth by A3AR agonist
    Pnina Fishman
    Can Fite BioPharma Ltd, Kiryat Matalon, Laboratory of Clinical and Tumor Immunology, Felsenstein Medical Research Center, Tel Aviv University Sackler Faculty of Medicine, Rabin Medical Center, Petach Tikva, Israel
    Anticancer Res 23:2077-83. 2003
  2. ncbi request reprint A3 adenosine receptor as a target for cancer therapy
    Pnina Fishman
    Laboratory of Clinical and Tumor Immunology, The Felsenstein Medical Research Center, Tel Aviv University, Rabin Medical Center, Petach Tikva 49100, Israel
    Anticancer Drugs 13:437-43. 2002
  3. ncbi request reprint Evidence for involvement of Wnt signaling pathway in IB-MECA mediated suppression of melanoma cells
    Pnina Fishman
    Laboratory of Clinical and Tumor Immunology, The Felsenstein Medical Research Center, Tel Aviv University, Sackler Faculty of Medicine, Rabin Medical Center, Petach Tikva 49100, Israel
    Oncogene 21:4060-4. 2002
  4. ncbi request reprint The A3 adenosine receptor as a new target for cancer therapy and chemoprotection
    P Fishman
    Laboratory of Clinical and Tumor Immunology, Rabin Medical Center, Petach Tikva, 49100, Israel
    Exp Cell Res 269:230-6. 2001
  5. ncbi request reprint Adenosine acts as a chemoprotective agent by stimulating G-CSF production: a role for A1 and A3 adenosine receptors
    P Fishman
    Laboratory of Clinical and Tumor Immunology, The Felsenstein Medical Research Center, Tel Aviv University, Rabin Medical Center, Petach Tikva, Israel
    J Cell Physiol 183:393-8. 2000
  6. pmc CF102 an A3 adenosine receptor agonist mediates anti-tumor and anti-inflammatory effects in the liver
    S Cohen
    Can Fite BioPharma Ltd, Kiryat Matalon, Petach Tikva, Israel
    J Cell Physiol 226:2438-47. 2011
  7. ncbi request reprint The A3 adenosine receptor agonist CF102 induces apoptosis of hepatocellular carcinoma via de-regulation of the Wnt and NF-kappaB signal transduction pathways
    S Bar-Yehuda
    Can Fite BioPharma Ltd, Kiryat Matalon, Petach Tikva 49170, Israel
    Int J Oncol 33:287-95. 2008
  8. ncbi request reprint The anti-inflammatory target A(3) adenosine receptor is over-expressed in rheumatoid arthritis, psoriasis and Crohn's disease
    A Ochaion
    Can Fite BioPharma Ltd, Kiryat Matalon, Petah Tikva, Israel
    Cell Immunol 258:115-22. 2009
  9. ncbi request reprint Adenosine acts as an inhibitor of lymphoma cell growth: a major role for the A3 adenosine receptor
    P Fishman
    Laboratory of Clinical and Tumor Immunology, The Felsenstein Medical Research Center, Tel Aviv University, Rabin Medical Center, Petach Tikva, Israel
    Eur J Cancer 36:1452-8. 2000
  10. pmc Resistance of muscle to tumor metastases: a role for a3 adenosine receptor agonists
    S Bar-Yehuda
    Laboratory of Clinical and Tumor Immunology, The Felsenstein Medical Research Center, Sackler Faculty of Medicine, Tel-Aviv University, Rabin Medical Center, Petach Tikva, Israel
    Neoplasia 3:125-31. 2001

Collaborators

  • Sara Bar-Yehuda
  • S Pathak
  • K A Jacobson
  • M David
  • S Ben-Horin
  • Ofer Merimsky
  • Moshe Mittelman
  • K Khalili
  • Y Shoenfeld
  • Lea Madi
  • A Ochaion
  • S Cohen
  • Avivit Ochaion
  • F Barer
  • L Rath-Wolfson
  • Faina Barer
  • R Patoka
  • G Ohana
  • Arie Harish
  • H Amital
  • Michael H Silverman
  • Shira Cohen
  • Tatiana Reitblat
  • Reuven Mader
  • Motti Farbstein
  • Yair Molad
  • Pnina Langevitz
  • Moshe Tishler
  • Sari Fishman-Furman
  • Ehud Baharav
  • Lea Rath-Wolfson
  • L Madi
  • G Zozulya
  • S M Stemmer
  • T Reitblat
  • J Ophir
  • I Konfino
  • A Reitblat
  • Y Chowers
  • Alan Rubinow
  • Dan Caspi
  • Z G Gao
  • L del Valle
  • Muhamad Adawi
  • Ilan Cohn
  • G Perez-Liz
  • B V Joshi
  • Vibeke Strand
  • Michael Rozenbaum
  • William D Kerns
  • Menachem Nahir
  • Amir Tanay
  • Doron Markovits
  • Joshua Friedman
  • Lesly Green
  • Itzhak Rosner
  • Sara Bar Yehuda
  • Avivit Ochayin
  • Alexander Zabutti
  • Yair Levi
  • Luis Del Valle
  • Alexander Reitblat
  • Georginia Perez-Liz
  • Howard Amital
  • A Zabutti
  • Shira Cohn
  • Marisa Halpren
  • Abraham Weinberger
  • Daniel Silberman
  • Abigail Erlanger
  • Ofer Merimski
  • Gil Ohana
  • Z Dreznick
  • Oshra Arnon
  • Gil Hohana
  • Eti Ardon
  • G Slosman
  • A Arich
  • D Silberman

Detail Information

Publications31

  1. ncbi request reprint Targeting the A3 adenosine receptor for cancer therapy: inhibition of prostate carcinoma cell growth by A3AR agonist
    Pnina Fishman
    Can Fite BioPharma Ltd, Kiryat Matalon, Laboratory of Clinical and Tumor Immunology, Felsenstein Medical Research Center, Tel Aviv University Sackler Faculty of Medicine, Rabin Medical Center, Petach Tikva, Israel
    Anticancer Res 23:2077-83. 2003
    ....
  2. ncbi request reprint A3 adenosine receptor as a target for cancer therapy
    Pnina Fishman
    Laboratory of Clinical and Tumor Immunology, The Felsenstein Medical Research Center, Tel Aviv University, Rabin Medical Center, Petach Tikva 49100, Israel
    Anticancer Drugs 13:437-43. 2002
    ..The A3AR agonists are thus a promising new class of agents for cancer therapy...
  3. ncbi request reprint Evidence for involvement of Wnt signaling pathway in IB-MECA mediated suppression of melanoma cells
    Pnina Fishman
    Laboratory of Clinical and Tumor Immunology, The Felsenstein Medical Research Center, Tel Aviv University, Sackler Faculty of Medicine, Rabin Medical Center, Petach Tikva 49100, Israel
    Oncogene 21:4060-4. 2002
    ..These observations which link cAMP to the Wnt signaling pathway provide mechanistic evidence for the involvement of Wnt pathway via its key elements GSK-3beta and beta-catenin in the anti-tumor activity of A3AR agonists...
  4. ncbi request reprint The A3 adenosine receptor as a new target for cancer therapy and chemoprotection
    P Fishman
    Laboratory of Clinical and Tumor Immunology, Rabin Medical Center, Petach Tikva, 49100, Israel
    Exp Cell Res 269:230-6. 2001
    ..We conclude that A3 adenosine receptor agonist, Cl-IB-MECA, exhibits systemic anticancer and chemoprotective effects...
  5. ncbi request reprint Adenosine acts as a chemoprotective agent by stimulating G-CSF production: a role for A1 and A3 adenosine receptors
    P Fishman
    Laboratory of Clinical and Tumor Immunology, The Felsenstein Medical Research Center, Tel Aviv University, Rabin Medical Center, Petach Tikva, Israel
    J Cell Physiol 183:393-8. 2000
    ..It is suggested that low-dose adenosine, already in clinical use, may also be applied as a chemoprotective agent...
  6. pmc CF102 an A3 adenosine receptor agonist mediates anti-tumor and anti-inflammatory effects in the liver
    S Cohen
    Can Fite BioPharma Ltd, Kiryat Matalon, Petach Tikva, Israel
    J Cell Physiol 226:2438-47. 2011
    ..These results suggest that CF102 through its differential effect is a potential drug candidate to treat various pathological liver conditions...
  7. ncbi request reprint The A3 adenosine receptor agonist CF102 induces apoptosis of hepatocellular carcinoma via de-regulation of the Wnt and NF-kappaB signal transduction pathways
    S Bar-Yehuda
    Can Fite BioPharma Ltd, Kiryat Matalon, Petach Tikva 49170, Israel
    Int J Oncol 33:287-95. 2008
    ..Taken together, A(3)AR is highly expressed in tumors and PBMCs of HCC patients and tumor-bearing rats. CF102 induced apoptosis and tumor growth inhibition. These data suggest A(3)AR as a novel targeted therapy to treat HCC...
  8. ncbi request reprint The anti-inflammatory target A(3) adenosine receptor is over-expressed in rheumatoid arthritis, psoriasis and Crohn's disease
    A Ochaion
    Can Fite BioPharma Ltd, Kiryat Matalon, Petah Tikva, Israel
    Cell Immunol 258:115-22. 2009
    ..Taken together, NF-kappaB and CREB are involved with the over-expression of A(3)AR in patients with autoimmune inflammatory diseases. The receptor may be considered as a specific target to combat inflammation...
  9. ncbi request reprint Adenosine acts as an inhibitor of lymphoma cell growth: a major role for the A3 adenosine receptor
    P Fishman
    Laboratory of Clinical and Tumor Immunology, The Felsenstein Medical Research Center, Tel Aviv University, Rabin Medical Center, Petach Tikva, Israel
    Eur J Cancer 36:1452-8. 2000
    ..The cytostatic anticancer activity, mediated through the A3 adenosine receptor, turns it into a potential target for the development of anticancer therapies...
  10. pmc Resistance of muscle to tumor metastases: a role for a3 adenosine receptor agonists
    S Bar-Yehuda
    Laboratory of Clinical and Tumor Immunology, The Felsenstein Medical Research Center, Sackler Faculty of Medicine, Tel-Aviv University, Rabin Medical Center, Petach Tikva, Israel
    Neoplasia 3:125-31. 2001
    ..These agonists are stable nondegradable molecules and may contribute to the systemic anticancer and chemoprotective activity exerted by MCM. This group of molecules may account for the rarity of tumor metastases in muscle...
  11. ncbi request reprint Adenosine and other low molecular weight factors released by muscle cells inhibit tumor cell growth
    P Fishman
    Laboratory of Clinical and Tumor Immunology, The Felsenstein Medical Research Center, Tel Aviv University, Rabin Medical Center, Petach Tikva, Israel
    Cancer Res 58:3181-7. 1998
    ..The ability of adenosine and other low molecular weight components to specifically inhibit tumor cell growth in vitro and in vivo may account for the resistance of muscle to tumor metastases...
  12. ncbi request reprint Differential effect of adenosine on tumor and normal cell growth: focus on the A3 adenosine receptor
    G Ohana
    Laboratory of Clinical and Tumor Immunology, The Felsenstein Medical Research Center, Tel-Aviv University, Petach-Tikva, Israel
    J Cell Physiol 186:19-23. 2001
    ..Taken together, activation of the A3AR, by minute concentrations of its natural ligand or synthetic agonists, may serve as a new approach for cancer therapy...
  13. pmc The A3 adenosine receptor agonist CF502 inhibits the PI3K, PKB/Akt and NF-kappaB signaling pathway in synoviocytes from rheumatoid arthritis patients and in adjuvant-induced arthritis rats
    A Ochaion
    Can Fite BioPharma Ltd, Kiryat Matalon, Petah Tikva 49170, Israel
    Biochem Pharmacol 76:482-94. 2008
    ..Taken together, CF502 inhibits FLS growth and the inflammatory manifestations of arthritis, supporting the development of A(3)AR agonists for the treatment of rheumatoid arthritis...
  14. pmc Inhibition of primary colon carcinoma growth and liver metastasis by the A3 adenosine receptor agonist CF101
    G Ohana
    Department of Surgery A B, Rabin Medical Center, Campus Golda, Sackler Faculty of Medicine Tel Aviv University, Petach Tikva 49100, Israel
    Br J Cancer 89:1552-8. 2003
    ....
  15. ncbi request reprint IB-MECA, an A3 adenosine receptor agonist prevents bone resorption in rats with adjuvant induced arthritis
    L Rath-Wolfson
    Can Fite BioPharma Ltd, Kiryat Matalon, Petah Tikva, Israel
    Clin Exp Rheumatol 24:400-6. 2006
    ..In this study we tested the effect of IB-MECA on the prevention of bone resorption in AIA rats and looked at the molecular mechanism of action...
  16. doi request reprint Treatment of plaque-type psoriasis with oral CF101: data from an exploratory randomized phase 2 clinical trial
    M David
    Department of Dermatology, Rabin Medical Center, Tel Aviv University, Petah Tikva, Israel
    J Eur Acad Dermatol Venereol 26:361-7. 2012
    ..The aim of this study was to evaluate the safety and efficacy of CF101 for the treatment of patients with moderate to severe plaque-type psoriasis...
  17. ncbi request reprint IVIg to prevent tumor metastases (Review)
    Pnina Fishman
    Felsenstein Medical Research Center, Rabin Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Petach Tikva 49100, Israel
    Int J Oncol 21:875-80. 2002
    ..The lack of serious side effects with the remarkable decrease in metastatic spread make IVIg a suitable adjuvant therapy in early and advanced cancer conditions...
  18. ncbi request reprint A3 adenosine receptor activation in melanoma cells: association between receptor fate and tumor growth inhibition
    Lea Madi
    Can Fite BioPharma Ltd, Kiryat Matalon, Petach Tikva 49170, Israel
    J Biol Chem 278:42121-30. 2003
    ..Altogether, our observations tie the fate of A3AR to modulation of downstream molecular mechanisms leading to tumor growth inhibition both in vitro and in vivo...
  19. ncbi request reprint Agonists to the A3 adenosine receptor induce G-CSF production via NF-kappaB activation: a new class of myeloprotective agents
    Sara Bar-Yehuda
    Laboratory of Clinical and Tumor Immunology, The Felsenstein Medical Research Center, Sackler Faculty of Medicine, Tel Aviv University, Rabin Medical Center, Petach Tikva, 49100 Israel
    Exp Hematol 30:1390-8. 2002
    ..The ability of CF101 to act as a myeloprotective agent in chemotherapy-treated mice was tested...
  20. ncbi request reprint Overexpression of A3 adenosine receptor in peripheral blood mononuclear cells in rheumatoid arthritis: involvement of nuclear factor-kappaB in mediating receptor level
    Lea Madi
    Can Fite BioPharma Ltd, Kiryat Matalon, Petah Tikva, Israel
    J Rheumatol 34:20-6. 2007
    ..We examined the role of nuclear factor-kappaB (NF-kappaB), a transcription factor present in the A3AR promoter, in mediating receptor upregulation...
  21. pmc Methotrexate enhances the anti-inflammatory effect of CF101 via up-regulation of the A3 adenosine receptor expression
    Avivit Ochaion
    Can Fite BioPharma Ltd, 10 Bareket Street, Kiryat Matalon, Petah Tikva, 49170, Israel
    Arthritis Res Ther 8:R169. 2006
    ..In conclusion, the data presented here indicate that MTX induces increased A3AR expression and exhibition, thereby potentiating the inhibitory effect of CF101 and supporting combined use of these drugs to treat RA...
  22. ncbi request reprint A3 adenosine receptor agonist potentiates natural killer cell activity
    Arie Harish
    Department of Surgery A B and Pathology, Rabin Medical Center, Campus Golda, Sackler Faculty of Medicine, Tel Aviv University, Petach Tikva 49100, Israel
    Int J Oncol 23:1245-9. 2003
    ..Taken together, the ability of Cl-IB-MECA to inhibit tumor development via the activation of NK cells is an additional mechanism which accounts for the anti-tumor effect of A3AR agonists...
  23. pmc The PI3K-NF-kappaB signal transduction pathway is involved in mediating the anti-inflammatory effect of IB-MECA in adjuvant-induced arthritis
    Pnina Fishman
    Can Fite BioPharma Ltd, Kiryat Matalon, Petah Tikva, Israel
    Arthritis Res Ther 8:R33. 2006
    ..The finding that the A3AR expression level in the peripheral blood mononuclear cells and in the DLN reflects the receptor status in the remote inflammatory site suggests use of the A3AR as a follow-up biomarker...
  24. pmc CF101, an agonist to the A3 adenosine receptor, enhances the chemotherapeutic effect of 5-fluorouracil in a colon carcinoma murine model
    Sara Bar-Yehuda
    Can Fite BioPharma Ltd, Kiryat Matalon, Petach Tikva 49170, Israel
    Neoplasia 7:85-90. 2005
    ..These results show that CF101 potentiates the cytotoxic effect of 5-FU, thus preventing drug resistance. The myeloprotective effect of CF101 suggests its development as an add-on treatment to 5-FU...
  25. ncbi request reprint The A3 adenosine receptor is highly expressed in tumor versus normal cells: potential target for tumor growth inhibition
    Lea Madi
    Can Fite BioPharma Ltd, Kiryat Matalon, Petach Tikva, Israel
    Clin Cancer Res 10:4472-9. 2004
    ..To additionally elucidate whether A(3)AR is a specific target, a survey of its expression in tumor versus adjacent normal cells was conducted...
  26. ncbi request reprint An agonist to the A3 adenosine receptor inhibits colon carcinoma growth in mice via modulation of GSK-3 beta and NF-kappa B
    Pnina Fishman
    Can Fite BioPharma Ltd, Kiryat Matalon, Petach Tikva 49170, Israel
    Oncogene 23:2465-71. 2004
    ..This is the first demonstration that A(3)AR activation induces colon carcinoma growth inhibition via the modulation of the key proteins GSK-3 beta and NF-kappa B...
  27. ncbi request reprint Pharmacology and therapeutic applications of A3 receptor subtype
    Pnina Fishman
    Laboratory of Clinical and Tumor Immunology, The Felsenstein Medical Research Center, Sackler School of Medicine, Tel Aviv University, Rabin Medical Center, Petach Tikva, Israel
    Curr Top Med Chem 3:463-9. 2003
    ..Antagonists to A(3)AR may be implemented to the therapy of asthma and additional allergic conditions...
  28. ncbi request reprint Antiinflammatory effect of A3 adenosine receptor agonists in murine autoimmune arthritis models
    Ehud Baharav
    Can Fite BioPharma Ltd, 10 Bareket Street, Kiryat Matalon, Petach Tikva, Tel Aviv, Israel 49170
    J Rheumatol 32:469-76. 2005
    ..We evaluated its therapeutic potential and antiinflammatory effects in 3 murine models of adjuvant induced arthritis (AIA)...
  29. ncbi request reprint The anti-inflammatory effect of A3 adenosine receptor agonists: a novel targeted therapy for rheumatoid arthritis
    Sara Bar-Yehuda
    Can Fite BioPharma, 10 Bareket Street, PO Box 7537, Petach Tikva 49170, Israel
    Expert Opin Investig Drugs 16:1601-13. 2007
    ..Taken together, this information suggests that A(3)AR agonists may be a new family of orally bioavailable drugs to be developed as potent inhibitors of autoimmune-inflammatory diseases...
  30. ncbi request reprint Clinical evidence for utilization of the A3 adenosine receptor as a target to treat rheumatoid arthritis: data from a phase II clinical trial
    Michael H Silverman
    Can Fite BioPharma Ltd, Petach Tikva, Israel
    J Rheumatol 35:41-8. 2008
    ..CF101 is a highly specific orally bioavailable A3AR agonist...
  31. ncbi request reprint A possible role for IVIg in the treatment of soft tissue sarcoma: a clinical case and an experimental model
    Ofer Merimsky
    Department of Oncology, Tel Aviv Sourasky Medical Center, Tel Aviv 64239, Israel
    Int J Oncol 20:839-43. 2002
    ..c. or oral administration, the latter being more effective. A possible role for IVIg in the treatment of MPNST and other soft tissue sarcomas is suggested...